United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

21 Oct 2016
Change (% chg)

$-0.10 (-0.50%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Acorda Therapeutics Inc reaffirms FY 2015 AMPYRA net revenue outlook
Thursday, 12 Feb 2015 06:00am EST 

Acorda Therapeutics Inc:Expects FY 2015 AMPYRA net revenue of $405-$420 mln.  Full Article

Acorda Therapeutics Inc announces safety and tolerability data from First clinical trial of Remyelinating Antibody in Multiple Sclerosis
Monday, 2 Feb 2015 07:01am EST 

Acorda Therapeutics Inc:Announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS).Says the trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied.Says based on these data, the company intends to advance clinical development of rHIgM22.Says this was a multi-center, double-blind, randomized, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of a single dose of rHIgM22 in participants with any type of MS who were clinically stable for at least three months.Says all participants remained on their existing MS treatment regimens, including disease-modifying therapies.Says the first part of the study included five cohorts, with each cohort receiving a higher dose of rHIgM22 than the previous one.Says the second part of the study, 21 treatment-naïve participants were randomized to receive placebo or one of the two highest doses of rHIgM22 from the first part of the study.Says second part of the study also included several exploratory clinical, imaging and biomarker measures, which are still being analyzed.Says the study was not powered to determine statistical significance on these measures.  Full Article

Acorda Therapeutics Inc gives FY 2015 revenue outlook in line with analysts' estimates
Monday, 12 Jan 2015 06:01am EST 

Acorda Therapeutics Inc:Expects FY 2015 net sales in the range of $405-$420 mln.FY 2015 revenue of $414 mln - Thomson Reuters I/B/E/S.  Full Article

Acorda Therapeutics Inc announces initiation of phase 3 clinical trial for Dalfampridine in Post-Stroke Walking Deficits
Monday, 15 Dec 2014 07:01am EST 

Acorda Therapeutics Inc:Says the first patient has been enrolled in a Phase 3 clinical trial of dalfampridine for the treatment of post-stroke walking deficits (PSWD).Says this multi-center, double-blind, randomized trial is expected to enroll about 540 participants who have experienced an ischemic stroke at least six months prior to enrollment.Says participants will receive 10 mg dalfampridine, 7.5 mg dalfampridine, or placebo twice daily for 12 weeks.Says the primary endpoint of the study is the percentage of patients taking dalfampridine who demonstrate at least a 20 pct improvement in the 2 Minute Walk Test (2MinWT) compared to those receiving placebo.Says the 2MinWT measures the distance a person can walk in 2 minutes.Says other measures will include the Timed Up and Go, which assesses mobility and balance, as well as clinician and patient-reported measures.Says the study also includes evaluation of safety and tolerability.  Full Article

BRIEF-Acorda Therapeutics presents data from clinical and preclinical trials of CVT-301

* Acorda Therapeutics Inc-presents data from clinical and preclinical trials of CVT-301 for treatment of OFF periods in Parkinson's disease